Eli Lilly and Company (LLY)vsTravere Therapeutics Inc (TVTX)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
TVTX
Travere Therapeutics Inc
$40.10
-1.93%
HEALTHCARE · Cap: $3.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 13182% more annual revenue ($65.18B vs $490.73M). LLY leads profitability with a 31.7% profit margin vs -5.2%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TVTX
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+50.9%
Fair Value
$61.58
Current Price
$40.10
$21.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 73.4% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
Trading at 31.8x book value
ROE of -57.8% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : TVTX
The strongest argument for TVTX centers on Revenue Growth. Revenue growth of 73.4% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : TVTX
The primary concerns for TVTX are EPS Growth, Price/Book, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while TVTX is a hypergrowth play — different risk/reward profiles.
TVTX carries more volatility with a beta of 0.87 — expect wider price swings.
TVTX is growing revenue faster at 73.4% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 32/100), backed by strong 31.7% margins and 42.6% revenue growth. TVTX offers better value entry with a 50.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Travere Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?